SCHEMBL289519

SCHEMBL289519

CCOC(=O)c1sc(N)nc1C(C)(C)C

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 1.00
HPGD P15428 3/20 1.00
CYP1A2 P05177 1/20 0.65
HSD17B10 Q99714 3/20 0.58
DHODH Q02127 3/20 0.52
LMNA P02545 1/20 0.49
KMT2A Q03164 3/20 0.48
MEN1 O00255 2/20 0.48
CDC7 O00311 2/20 0.47
DBF4 Q9UBU7 2/20 0.47
MAPT P10636 4/20 0.46
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
FBP1 P09467 1/20 0.46
GAA P10253 3/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
KDM4E B2RXH2 2/20 0.44
GLA P06280 1/20 0.44
CASP1 P29466 1/20 0.44
CASP7 P55210 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL244255 0.86 ALDH1A1 (0.76) ALDH1A1HPGDCYP1A2HSD17B10LMNA
SCHEMBL10242354 0.84 ALDH1A1 (0.72) ALDH1A1HPGDCYP1A2HSD17B10DHODH
SCHEMBL882389 0.84 ALDH1A1 (0.72) ALDH1A1HPGDCYP1A2HSD17B10LMNA
SCHEMBL10820916 0.81 ALDH1A1 (0.68) ALDH1A1HPGDCYP1A2HSD17B10DHODH
SCHEMBL244752 0.80 ALDH1A1 (0.73) ALDH1A1HPGDCYP1A2HSD17B10LMNA
SCHEMBL3098533 0.79 ALDH1A1 (0.65) ALDH1A1HPGDCYP1A2HSD17B10LMNA
SCHEMBL3921966 0.79 ALDH1A1 (0.71) ALDH1A1HPGDCYP1A2HSD17B10LMNA
Hydrochloric Acid SCHEMBL8114168 0.79 ALDH1A1 (0.71) ALDH1A1HPGDCYP1A2HSD17B10LMNA
SCHEMBL3119761 0.79 ALDH1A1 (1.00) ALDH1A1HPGDCYP1A2HSD17B10LMNA
SCHEMBL23703077 0.78 ALDH1A1 (0.69) ALDH1A1HPGDCYP1A2HSD17B10LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4308391-A 2-Amino-4-substituted-thiazolecarboxylic acids and their derivatives MONSANTO COMPANY (US) 1981-12-29 US claimed
US-20180243298-A1 TRPV3 MODULATORS ABBVIE INC. 2018-08-30 US disclosed
WO-2016160938-A1 N-(1,3-THIAZOL-2-YL)PYRIMIDINE-5-CARBOXAMIDES AS TRPV3 MODULATORS ABBVIE INC. (US) 2016-10-06 WO disclosed
US-8263657-B2 Blocking neurokinins; using a benzene compound containing hydroxy or acetoxy group; antiinflammatory agents INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2012-09-11 US disclosed
EP-2427447-A2 SMALL MOLECULE INHIBITORS OF INFLUENZA A AND B VIRUS AND RESPIRATORY SYNCYTIAL VIRUS REPLICATION Pike Pharma GmbH (CH) 2012-03-14 EP disclosed
US-8097759-B2 Inflammatory cytokine release inhibitor INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2012-01-17 US disclosed
WO-2010128163-A2 SMALL MOLECULE INHIBITORS OF INFLUENZA A AND B VIRUS AND RESPIRATORY SYNCYTIAL VIRUS REPLICATION PIKE PHARMA GMBH (CH) 2010-11-11 WO disclosed
US-20100274051-A1 INFLAMMATORY CYTOKINE RELEASE INHIBITOR INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) 2010-10-28 US disclosed
US-7700655-B2 Antiallergic agents INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2010-04-20 US disclosed
US-20090192122-A2 INFLAMMATORY CYTOKINE RELEASE INHIBITOR INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2009-07-30 US disclosed
EP-1535609-A1 NF-KB ACTIVATION INHIBITORS Institute of Medicinal Molecular Design, Inc. (JP) 2005-06-01 EP disclosed
EP-1514544-A1 ANTIALLERGIC Institute of Medicinal Molecular Design, Inc. (JP) 2005-03-16 EP disclosed
EP-1512396-A1 INHIBITORS AGAINST THE ACTIVATION OF AP-1 AND NFAT Institute of Medicinal Molecular Design, Inc. (JP) 2005-03-09 EP disclosed
EP-1510207-A1 THERAPEUTIC DRUG FOR DIABETES Institute of Medicinal Molecular Design, Inc. (JP) 2005-03-02 EP disclosed
EP-1510210-A1 IMMUNITY-RELATED PROTEIN KINASE INHIBITORS Institute of Medicinal Molecular Design, Inc. (JP) 2005-03-02 EP disclosed
US-20040259877-A1 Inhibitors against the production and release of inflammatory cytokines INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2004-12-23 US disclosed
EP-1352650-A1 INHIBITORS AGAINST THE PRODUCTION AND RELEASE OF INFLAMMATORY CYTOKINES Institute of Medicinal Molecular Design, Inc. (JP) 2003-10-15 EP disclosed
EP-0027018-B1 PROCESS FOR THE PRODUCTION OF 2-CHLORO-4-SUBSTITUTED-5-THIAZOLECARBOXYLATES MONSANTO COMPANY (US) 1983-10-05 EP disclosed
US-4308391-A 2-Amino-4-substituted-thiazolecarboxylic acids and their derivatives MONSANTO COMPANY (US) 1981-12-29 US disclosed
EP-0027018-A1 Process for the production of 2-chloro-4-substituted-5-thiazolecarboxylates MONSANTO COMPANY (US) 1981-04-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180243298-A1 TRPV3 MODULATORS TRPV3, TRPV1, TRPV2 ALDH1A1 3440/4885HPGD 869/4885CYP1A2 2617/4885
US-20100274051-A1 INFLAMMATORY CYTOKINE RELEASE INHIBITOR IL1B, NFKBIA, IL1A ALDH1A1 479/4885HPGD 272/4885CYP1A2 1547/4885
US-20090192122-A2 INFLAMMATORY CYTOKINE RELEASE INHIBITOR IL1B, NFKBIA, IL1A ALDH1A1 563/4885HPGD 238/4885CYP1A2 1583/4885
US-20040259877-A1 Inhibitors against the production and release of inflammatory cytokines NFKBIA, IL1B, IKBKB ALDH1A1 1025/4885HPGD 245/4885CYP1A2 1483/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.